Lymphedema, Perioperative/Postoperative Complications, Stage IA Vulvar Cancer AJCC v7, Stage IB Vulvar Cancer AJCC v7, Stage II Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7, Stage IVA Vulvar Cancer AJCC v7, Stage IVB Vulvar Cancer AJCC v6 and v7
Conditions
Brief summary
This phase II trial studies bioimpedance spectroscopy in detecting lower-extremity lymphedema in patients with stage I, stage II, stage III, or stage IV vulvar cancer undergoing surgery and lymphadenectomy. Diagnostic procedures, such as bioimpedance spectroscopy, may help doctors to predict the onset of lower-extremity lymphedema in patients with vulvar cancer undergoing surgery.
Detailed description
OBJECTIVES: I. To evaluate the sensitivity, specificity, and feasibility of bioimpedance technology as compared to clinically derived measurements to include circumferential volumetric measurements to detect lower-extremity lymphedema in patients who are undergoing an inguinal lymphadenectomy during the concurrent surgical management of a vulvar cancer. OUTLINE: This is a multicenter study. Patients undergo preoperative and postoperative lower-extremity lymphedema assessment comprising serial circumferential measurements, bioimpedance spectroscopy measurements, and clinical evaluation using the Stemmer sign. Patients undergo radical vulvectomy or radical local excision as prescribed by GOG-0244, and unilateral or bilateral inguinal or inguinal-femoral lymphadenectomy. After completion of study, patients are followed up at 4-6 weeks, every 3 months for 1 year, and then every 6 months for 1 year.
Interventions
PROCEDUREBioelectric Impedance Analysis
Undergo preoperative and postoperative lower-extremity lymphedema assessment
PROCEDURELymphadenectomy
Undergo lymphadenectomy
PROCEDURETherapeutic Conventional Surgery
Undergo radical vulvectomy or radical local excision
Sponsors
National Cancer Institute (NCI)
Gynecologic Oncology Group
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with vulvar cancer already enrolled onto Gynecologic Oncology Group (GOG)-0244 who will undergo or have undergone definitive surgery for primary stage I-IV vulvar cancer who will receive a radical vulvectomy or radical local excision with concurrent unilateral or bilateral inguinal or inguinal-femoral lymphadenectomy; * Patients who are going to receive multi-modality therapy (radiation +/- chemotherapy) after undergoing surgery are eligible * Patients who have met the pre-entry requirements * Patients must have signed an approved informed consent and authorization permitting release of personal health information for GOG-0269 and for GOG-0244 * Patients may undergo sentinel node mapping as long as it is followed by a full lymphadenectomy during the same operative event * Serum Albumin level of \>= 3.0 within 14 days of entry * Patients with a GOG performance status of 0, 1, or 2
Exclusion criteria
* Patients not enrolled onto GOG-0244 * Patients with any prior clinical history of lower extremity lymphedema * Patients who have a history of congestive heart failure, chronic renal disease, or chronic liver disease * Patients with a prior history of chronic lower extremity swelling * Patients with a GOG Performance Grade of 3 or 4 * Patients with a history of other invasive malignancies if that malignancy included a bilateral lymph node procedure (example: bilateral mastectomies and axillary lymphadenectomies) or if their previous cancer treatment included any of the surgical procedures * Patients who have had prior lower extremity vascular surgery (arterial or venous) * Patients who have had prior pelvic bilateral axillary or any pelvic, abdominal, inguinal, or lower extremity radiation therapy * Patients who are going to receive another elective surgery during the same operative event as their inguinal lymphadenectomy and vulvar surgery * Patients who undergo sentinel node biopsy without the intention of undergoing a complete lymphadenectomy during that same operative event * Patients with an implanted cardiac device such as a pacemaker or implantable cardioverter defibrillator * Patients who are pregnant or currently breastfeeding * Patients who have been treated for, or are at risk of, bilateral arm lymphedema * Patients with an allergic reaction to electrocardiogram (EKG) electrodes * Patients who have had bilateral auxiliary dissection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity, specificity, and feasibility of bioimpedance technology as compared to clinically derived measurements (limb volume and Stemmer Sign) | Up to 24 months post-operatively | The usual assessment of sensitivity and specificity using the volume based diagnosis as the ?Gold Standard? after an receiver operating characteristic (ROC) analysis to determine the cut-point for the definition of a diagnosis of lymphedema by the bioimpedance method will be performed. |
| Frequency and severity of adverse events using Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Up to 24 months | — |
Countries
United States
Outcome results
None listed